Research/Compounds/Tesamorelin + Ipamorelin Blend
BlendGH SecretagoguesFDA-Approved Component

Tesamorelin + Ipamorelin Blend

FDA-Approved GHRH + GHRP — Visceral Fat & Body Composition Stack

Tesamorelin half-life
~26 min
Route
SC
Typical dose
1-2mg Tesa / 200mcg Ipa
Tesamorelin
FDA-Approved

Blend Composition

Tesamorelin
variable
GHRH
FDA-approved GHRH analog — visceral fat reduction, GH pulse stimulation
Ipamorelin
variable
GHRP
Selective GH releasing peptide — amplifies GH pulse, minimal cortisol/prolactin

What is Tesamorelin + Ipamorelin Blend?

The Tesamorelin + Ipamorelin blend pairs the only FDA-approved GHRH analog (Tesamorelin, approved as Egrifta for HIV-associated lipodystrophy) with Ipamorelin's selective GH pulse amplification. The combination is used in optimization medicine for body composition, visceral fat reduction, and anti-aging protocols.

Tesamorelin is a stabilized GHRH analog with a 26-minute half-life. Unlike CJC-1295 No DAC, it has Phase III human trial data showing statistically significant reductions in visceral adipose tissue — the only GH secretagogue with this level of evidence for fat reduction specifically. Ipamorelin's addition amplifies the GH pulse through a separate receptor pathway.

This blend is particularly used by prescribing physicians in optimization and longevity medicine practices as a replacement or upgrade for CJC-1295 + Ipamorelin when greater evidence base and visceral fat specificity is desired.

Reconstitution

Tesamorelin is typically reconstituted with sterile water (not BAC water) per manufacturer specification when obtained through compounding. When blended with Ipamorelin, follow prescribing pharmacy instructions. Typical: 2mL diluent for a 2mg tesamorelin + 2mg ipamorelin blend vial.

Use the Reconstitution Calculator for exact amounts.

FAQ

What makes Tesamorelin different from CJC-1295?+
Tesamorelin has FDA approval for visceral fat reduction in HIV-associated lipodystrophy and has completed Phase III human clinical trials. CJC-1295 No DAC has no FDA approval and limited human trial data. Tesamorelin has the strongest evidence base of any GHRH analog for visceral adipose tissue reduction.
Is Tesamorelin legal?+
Tesamorelin has FDA approval as Egrifta for a specific indication. It is accessible through 503A compounding pharmacies for off-label use with a physician prescription in many jurisdictions. Verify current regulatory status with a licensed provider.
Why combine Tesamorelin with Ipamorelin?+
Tesamorelin stimulates GH release via the GHRH receptor. Ipamorelin acts on the ghrelin receptor (GHSR) — a separate pathway that potentiates the GH pulse. Combining them produces a synergistic effect greater than either alone, similar to the CJC-1295 + Ipamorelin rationale.
What are the clinical outcomes for Tesamorelin?+
Phase III trials showed statistically significant reductions in visceral adipose tissue (VAT) compared to placebo, with IGF-1 normalization. Visceral fat reduction is one of the most clinically documented effects of any GH secretagogue in human trials.

Related Compounds

TesamorelinIpamorelinCJC-1295 + Ipamorelin BlendSermorelin

For educational and research purposes only. Not medical advice.